Founded in 1984, Dr. Reddy’s Laboratories is an Indian multinational pharmaceutical company headquartered in Hyderabad, Telangana, India. The company specializes in the research, development, manufacturing, and marketing of a wide range of pharmaceutical products.

Dr. Reddy’s Laboratories operates in multiple segments, including pharmaceutical services and active ingredients (PSAI), global generics, proprietary products, and biologics. It offers a diverse portfolio of over 200 products in various therapeutic categories such as cardiovascular, oncology, gastroenterology, dermatology, and neurology, among others.

The company also manufactures and markets branded generics, biosimilars, and custom pharmaceutical services. On a global scale, Dr. Reddy’s Laboratories has a significant presence across 25 countries, with offices and facilities in North America, Europe, Russia, CIS, India, and other emerging markets.

The company has established a strong distribution network, enabling its products to reach customers in more than 100 countries worldwide. Dr. Reddy’s Laboratories has several noteworthy subsidiaries, joint ventures, and partnerships.

These include North Carolina-based Dr. Reddy's Laboratories, Inc., which focuses on research and development, and Biocodex, a French multinational pharmaceutical company in which Dr. Reddy’s holds a 70% stake.

In terms of market position, Dr. Reddy’s Laboratories is ranked among the top pharmaceutical companies globally. It has consistently recorded impressive global sales figures, generating significant revenue through its diverse product offerings.

The company competes against other multinational pharmaceutical giants such as Pfizer, Novartis, and Roche. Over the years, Dr. Reddy’s Laboratories has achieved various milestones and significant developments.

In 2009, the company became the first Indian pharmaceutical company to launch a generic biologic in India with the introduction of a biosimilar version of Erythropoietin. In 2020, Dr. Reddy’s Laboratories partnered with the Russian Direct Investment Fund (RDIF) to conduct clinical trials and distribute the Sputnik V COVID-19 vaccine in India.

As of the latest update, Dr. Reddy’s Laboratories continues to be a leading player in the pharmaceutical industry, constantly exploring new opportunities for expansion and growth. The company remains committed to its mission of providing affordable and accessible healthcare solutions to people worldwide